Integrated Diagnostics (IDHC) investor relations material

Executive summary

• Achieved strong operational and financial growth in H1 2026, with revenue up 37% year-over-year to EGP 4.9 billion, driven by a 20% increase in test volumes and a 14% rise in average revenue per test.

• Net profit rose 47% to EGP 839 million; adjusted net profit up 40% to EGP 802 million, excluding FX gains/losses.

• Expanded leadership in Egypt, maintained stable progress in Jordan, advanced turnaround in Nigeria, and accelerated ramp-up in Saudi Arabia.

• Branch network expanded by 161 to 839 branches, with significant growth in Egypt, Jordan, and Saudi Arabia.

• Hena Holdings increased its ownership to 56.67% following a mandatory takeover offer.

Financial highlights

• Gross profit increased 41% to EGP 2.1 billion; gross margin improved to 43.3%.

• EBITDA rose 38% to EGP 1.65 billion; EBITDA margin stable at 33.9%.

• Operating profit up 44% to EGP 1.33 billion; net profit margin expanded to 17.3%.

• Net cash balance at EGP 239 million; cash and financial assets at amortised cost stood at EGP 1.93 billion.

• Earnings per share increased to EGP 1.41 from EGP 0.95 year-over-year.

Outlook and guidance

• Forecasting FY 2026 revenue of EGP 11 billion, gross profit margin of 46%, EBITDA margin of 37%, and net profit margin of 20%.

• No further price increases planned for the rest of 2026.

• Expecting margin resilience and strong performance in H2 2026, with seasonality supporting higher margins.

• Plan to open around 50 more branches in Egypt in H2 2026; Saudi Arabia to reach nine branches by year-end and 50 branches in three years.

• Focus remains on expanding access to diagnostics, deepening specialised services, and enhancing value per patient.